The Ocuphire Investor R&D Day will feature six ophthalmic Key Opinion Leaders (KOLs) sharing their thoughts on three large unmet indications addressed by Ocuphire’s two late-stage clinical drug assets. Two of the three indications for Nyxol^®, reversal of mydriasis (reversing dilations) and presbyopia (age-related blurry near vision) will be discussed as will diabetic retinopathy (DR) indication for APX3330. Topics will include a review of previous Phase 2 and 3 readouts from 2021, status updates for ongoing clinical trials, a preview of 2022 catalysts, and prospective commercial dynamics and competitive positioning.

Ocuphire’s lead product candidate, Nyxol (0.75% phentolamine ophthalmic solution), is a non-selective alpha-1 and alpha-2 inhibitor for the treatment of front-of-the-eye conditions; its second product candidate, APX3330, is an oral Ref-1 inhibitor with a novel, dual anti-VEGF and anti-inflammatory mechanism for the treatment of diabetic retinal diseases.

Key Opinion Leaders:

Mina Sooch, CEO and Founder of Ocuphire, will provide a company overview. Dr. Kaiser and Dr. Boyer will present APX3330’s prior clinical safety data and provide an update on the ongoing ZETA-1 Phase 2b DR study. Dr. Jackson and Dr. Karpecki will discuss the positive Phase 3 MIRA-2 results for Nyxol for treating reversal of mydriasis, and the large addressable market potential of Nyxol. Lastly, Dr. Katz and Dr. Pepose will discuss the positive presbyopia VEGA-1 Phase 2 results in light of the competitive landscape and updates on the VEGA Phase 3 clinical programs. The discussion will also focus on the current patient-physician dynamic in the large market with over 100 million patients given the recent launch of Vuity™ by Allergan (an AbbVie Company), the first FDA-approved eyedrop treatment for presbyopia.

Each of these presentations will be followed by a live Q&A session.